Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (681-690 of 1,058) with videos related to

Pageof 106
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2015
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemiaJames S Blachly, Amy S Ruppert, Weiqiang Zhao, et al.
Hematological Oncology|April 3, 2023
Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization resultsMatthew R Avenarius, Ying Huang, Jonathan Hyak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ C Byrd, T Murphy, R S Howard, et al.
Blood Advances|April 29, 2022
Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapyMax Yano, Chia Sharpe, J Rachel Lance, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2009
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumorsBhuvaneswari Ramaswamy, Tanios Bekaii-Saab, Larry J Schaaf, et al.
JCI Insight|August 9, 2021
Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatantSara Elgamal, Emanuele Cocucci, Ellen J Sass, et al.
Mabs|January 5, 2010
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphomaLapo Alinari, Valerie L White, Christian T Earl, et al.
Leukemia|August 8, 2020
Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutationsAlice S Mims, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemiaRebecca B Klisovic, William Blum, Xiaohui Wei, et al.
Journal of Hematology & Oncology|March 19, 2013
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemiaHouda Alachkar, Ramasamy Santhanam, Jason G Harb, et al.
Pageof 106

Showing results (681-690 of 1,058) with videos related to

Sort By:
Pageof 106
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2015
Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemiaJames S Blachly, Amy S Ruppert, Weiqiang Zhao, et al.
Hematological Oncology|April 3, 2023
Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization resultsMatthew R Avenarius, Ying Huang, Jonathan Hyak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 17, 2001
Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ C Byrd, T Murphy, R S Howard, et al.
Blood Advances|April 29, 2022
Evaluation of allogeneic and autologous membrane-bound IL-21-expanded NK cells for chronic lymphocytic leukemia therapyMax Yano, Chia Sharpe, J Rachel Lance, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2009
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumorsBhuvaneswari Ramaswamy, Tanios Bekaii-Saab, Larry J Schaaf, et al.
JCI Insight|August 9, 2021
Optimizing extracellular vesicles' isolation from chronic lymphocytic leukemia patient plasma and cell line supernatantSara Elgamal, Emanuele Cocucci, Ellen J Sass, et al.
Mabs|January 5, 2010
Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphomaLapo Alinari, Valerie L White, Christian T Earl, et al.
Leukemia|August 8, 2020
Comparison of clinical and molecular characteristics of patients with acute myeloid leukemia and either TP73 or TP53 mutationsAlice S Mims, Jessica Kohlschmidt, Ann-Kathrin Eisfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemiaRebecca B Klisovic, William Blum, Xiaohui Wei, et al.
Journal of Hematology & Oncology|March 19, 2013
Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemiaHouda Alachkar, Ramasamy Santhanam, Jason G Harb, et al.
Pageof 106